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HIF1α activation in dendritic 
cells under sterile conditions 
promotes an anti‑inflammatory 
phenotype through accumulation 
of intracellular lipids
Elizabeth G. Wood1, Claire E. Macdougall1, Hazel Blythe1, Marc Clément2, Romain A. Colas1, 
Jesmond Dalli1, Federica Marelli‑Berg1 & M. Paula Longhi1*
Obesity is among the leading causes of elevated cardiovascular disease mortality and morbidity. 
Adipose tissue dysfunction, insulin resistance and inflammation are recognized as important risk 
factors for the development of cardiovascular disorders in obesity. Hypoxia appears to be a key factor 
in adipose tissue dysfunction affecting not only adipocytes but also immune cell function. Here we 
examined the effect of hypoxia‑induced transcription factor HIF1α activation on classical dendritic cell 
(cDCs) function during obesity. We found that deletion of Hif1α on cDCs results in enhanced adipose‑
tissue inflammation and atherosclerotic plaque formation in a mouse model of obesity. This effect 
is mediated by HIF1α‑mediated increased lipid synthesis, accumulation of lipid droplets and alter 
synthesis of lipid mediators. Our findings demonstrate that HIF1α activation in cDCs is necessary to 
control vessel wall inflammation.
Classical dendritic cells (cDCs) are the main antigen presenting cells and key regulators of immune homeostasis 
and  immunity1. Constantly probing their surroundings, cDCs are poised to detect invading pathogens, initiate 
and direct adaptive immune responses. cDCs are found in peripheral tissue in an immature state, where they 
sense and sample the environment for self- and non-self-antigens. Under pathogen driven danger signals, e.g. 
toll-like receptor (TLR), cDCs undergo an intricate maturation process characterized by increased expression of 
co-stimulatory molecules, cytokine/chemokine production and enhanced migration to draining lymph nodes 
(dLN) to present antigen to naïve T  cells1. In tissue, cDCs must adapt to specific metabolic cues such as nutrient 
restriction or low  O2 tensions, which may modulate their biological functions. Indeed, in recent years it became 
apparent that disruption of key metabolic pathways can alter immune cell activation and differentiation.
Reduced oxygen or hypoxia, is a hallmark of multiple acute and chronic diseases and arises especially in 
inflamed tissues. Cellular adaptation to hypoxia rely on stabilization of the hypoxia-inducible factor-1 (HIF1) 
transcription factor, which drives the metabolic changes required for adaptation to hostile microenvironments. 
HIF1 is a heterodimer transcription factor consisting of a constitutively expressed β-subunit (HIF1β) and an 
oxygen-regulated α subunit (HIF1α)2. Under normoxic conditions, HIF1α is regulated through hydroxylation 
of proline residues, ubiquitination and rapid degradation by the proteasome. Under low oxygen concentra-
tions, however, prolyl hydroxylase is inactivated and HIF1α can translocate into the nucleus for transcriptional 
regulation. HIF1α accumulation does not always occur under low  O2 tension but can be triggered by oxygen-
independent signalling events or cellular stress, such as toll-like receptor signalling and reactive oxidase species 
(ROS)—a phenomenon known as ‘pseudohypoxia’3.
Activation of the hypoxia pathway is believed to fuel inflammation, largely due to HIF1α activation in mac-
rophages. Lipopolysaccharide (LPS) activation induces HIF1α protein accumulation in macrophages under 
normoxic  conditions4 leading to metabolic reprogramming, succinate release, and IL-1β  production5. HIF1α-
deficient macrophages exhibit impaired inflammatory responses, with reduced glycolytic rate, motility and 
 migration6. Similarly, toll-like receptor (TLR) activation in dendritic cells, leads to HIF1α stabilization, glucose 
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uptake and glycolytic metabolic  shift7,8. In this context, deletion of HIF1α results in decreased ATP production, 
cell survival and T cell  priming8–10. However, the effect of HIF1α on dendritic cells function remains contro-
versial. In other studies, particularly under hypoxic conditions, HIF1α activation has been shown to promote 
anti-inflammatory  response11,12. HIF1α has pleiotropic effects regulating hundreds of genes encoding glycolytic 
enzymes, glucose transporters, matrix metalloproteinases, angiogenic and survival factors, that may depend on 
time and context. In addition, these divergent reports may in fact be explained by differences in experimental 
conditions or cell type targeted.
The present study was designed to investigate the role of HIF1α activation in cDCs in an experimental model 
of obesity by using mice with HIF1α deletion specifically in cDCs. Contrary to what was expected, deletion of 
HIF1α in cDCs promoted adipose tissue inflammation and atherosclerotic plaque formation. This effect was 
mediated by intracellular lipid accumulation and altered production of lipid mediators, which translated into 
reduced T cell stimulation.
Results
Deletion of Hif1α in cDCs leads to increased adipose tissue inflammation under high lipid and 
cholesterol diet. Adipose tissue hypoxia has been causally implicated in obesity-induced inflammation 
and insulin resistance. Under lipid rich diet, adipocyte expansion decreases oxygen tension and ROS produc-
tion, which leads to rapid activation of HIF1α13,14. cDCs are present in visceral adipose tissue (VAT) where they 
control tissue  homeostasis15. To investigate the effect of HIF1α in cDCs under chronic, sterile inflammation, we 
generated cDC-specific Hif1α knockdown by crossing Zbtb46-CRE with Hif1αfl/fl mice. As Zbtb46 is expressed 
in some non-haematopoietic cells, we performed mice chimeras where irradiated C57BL/6 mice were reconsti-
tuted with bone marrow cells from Hif1αfl/fl × Zbtb46-CRE (referred to as Hif1α−/−) or HIF1αfl/+ × Zbtb46-CRE 
(referred to as WT) mice. HIF1α deletion is shown in Suppl Fig. S1A. Hif1α−/− or WT mice were fed a lipid-
rich diet (western diet) for 12 weeks, which resulted in HIF1α increase in cDCs (Fig. 1a). Surprisingly, dele-
tion of HIF1α in cDCs results in increased immune cell infiltration into visceral adipose tissue (VAT) from 
Hif1α−/− mice, with increased numbers of cDCs, T cells and decreased regulatory T cells (Tregs) (Fig. 1b,c; Suppl 
Fig. S1b). Expression of the co-stimulatory molecule CD86 remained unchanged (Suppl Fig. S1c). Production 
of IL-17 in VAT-infiltrated T cells was increased in Hif1α−/− compared to WT mice together with increased 
IFNγ production in lymph nodes (LN) (Fig. 1d; Suppl Fig. S1d). No differences were observed in splenic T cells 
(Fig. 1d). This contributes to the enhanced VAT inflammation in Hif1α−/− mice as detected by RT-PCR (Fig. 1e).
Chronic inflammation in VAT plays a central role in the development of obesity-related insulin resistance 
and systemic metabolic  abnormalities16. Thus, we evaluated if the increased inflammation in Hif1α−/− mice 
could translate into systemic metabolic abnormalities. Body and VAT weight were similar between mice (Suppl 
Fig. S1e,f). Hif1α−/− mice displayed a small increase in fasting glucose levels and serum insulin levels com-
pared to WT mice, albeit this was not significant (Fig. 1g,h). Circulating concentrations of adiponectin were 
reduced in Hif1α−/− mice indicative of adipocyte dysfunction (Fig. 1f–h). Despite signs of metabolic misbalance, 
Hif1α−/− mice showed no sign of increased glucose and insulin tolerance during a glucose tolerance (GTT) and 
insulin tolerance (ITT) test (Suppl Fig. S1g,h). Thus, the results presented here indicate that inhibition of the 
Hif1 pathways under chronic, low oxygen conditions, promotes cDC activation.
Deletion of Hif1α in cDCs accelerates the development of atherosclerosis. Obesity-induced 
chronic inflammation is tightly linked to the development of atherosclerotic  plaque17. The atherosclerotic plaque 
is characterized by arterial wall thickening, ROS production and reduced oxygen supply in certain areas of the 
vascular intima creating a hypoxic  milieu18. HIF1α expression was observed in macrophages and smooth muscle 
cells bordering the necrotic core, and was associated with inflammation and  angiogenesis19. In addition, arteries 
are surrounded by perivascular adipose tissue which, under metabolic abnormalities, appears to promote vascu-
lar dysfunction and  atherosclerosis20. Thus, we hypothesized that increased VAT inflammation in Hif1α−/− mice 
might have a negative impact on the development of atherosclerosis. To test this, lethally-irradiated low den-
sity lipoprotein receptor knockout (Ldlr−/−) mice were reconstituted with bone marrow from Hif1αfl/fl × Zbtb46-
CRE (referred as Hif1α−/− → Ldlr−/−) or HIF1αfl/+ × Zbtb46-CRE mice (referred as WT → Ldlr−/−). Ldlr−/− mice, 
under fat rich diet, are known to show elevated plasma cholesterol (25 mmol/L) and rapid atherosclerotic plaque 
 formation21.
Hif1α−/− → Ldlr−/− and WT → Ldlr−/− were fed a WD for 12 weeks, after which the presence of hypoxic 
cDCs in the atherosclerotic lesions was confirmed by pimonidazole staining (Fig. 2a). In agreement with 
increased VAT inflammation Hif1α−/− → Ldlr−/− mice had greater numbers of cDCs and T cells in atheroscle-
rotic lesions compared to WT → Ldlr−/− mice (Fig. 2b). The ratio of cDC subsets remains unchanged between 
Hif1α−/− → Ldlr−/− and control mice as well as the expression of CD86 (Suppl Fig. S2a,b). This was accompanied by 
enlarged draining lymph nodes (dLN) and increased T cell-mediated IFNγ production in Hif1α−/− → Ldlr−/− mice 
compared to controls (Fig. 2c; Suppl Fig. S2c). No differences were observed in the spleen (Fig. 2c; Suppl Fig. S2c). 
The numbers of LN migratory DCs (mDCs) and their CD86 expression remained constant (Suppl Fig. S2d,e). 
However, intracellular levels of IL12 were elevated in VAT-cDCs and mDC in Hif1α−/− → Ldlr−/− compared to 
control mice (Suppl Fig. S2f). Accordingly, Hif1α deficiency in cDCs was associated with a significant increase in 
atherosclerotic lesion development compared to control (Fig. 2d–f). Plasma cholesterol levels were comparable 
between the groups of mice (Fig. 2g). Similar to abdominal VAT, inflammatory markers in perivascular fat were 
increased in Hif1α−/− → Ldlr−/− compared to WT → Ldlr−/− mice (Fig. 2h).
To confirm that this phenotype was a consequence of increased cDC activation, we tested cDC T cell stimu-
latory capacity in vivo. Enhanced proliferation of ovalbumin (OVA)-specific  CD4+ T cells (OT-II) could be 
observed in the aorta, VAT and dLN but not spleen from Hif1α−/− → Ldlr−/− compared to control mice (Fig. 2i). 
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Similarly,  HIF1−/− cDCs isolated from VAT an dLN of obese mice showed enhanced OT-II cell proliferation 
ex vivo compared to WT cDCs (Suppl Fig. S2g). OVA uptake was not affected by Hif1α deletion (Suppl Fig. S2h). 
Thus, depletion of HIF1α in cDCs under sterile conditions appears to unleash their activation.
HIF1α induces intracellular lipid accumulation. Stabilization of HIF1α is known to promote aero-
bic glycolysis shifting the cells away from glucose oxidative phosphorylation. Upon TLR activation, HIF1α-
dependent glycolytic switch enables macrophages and cDCs to produce metabolic intermediates and to fulfil 
cellular energetic demands required for full  activation22 (Suppl Fig. S3a).
However, HIF1α has recently been shown to regulate mitochondrial glutamine metabolism (Suppl Fig. S3a). 
Glutamine once converted to α-ketoglutarate (αKG), can be either oxidized to succinate or reduced to isocitrate 
and then citrate by a mechanism known as reversed TCA cycle. The latter is favoured in cells where HIF1α is 
 stabilized23,24.
In an attempt to understand the metabolic changes induced by HIF1α in cDCs, we moved to an in vitro 
system where cDCs were generated from bone-marrow with Flt3 ligand (Flt3L) and Hif1α was activated with 
desferrioxamine (DFO) (Fig. 3a; Suppl Fig. S3b),which facilitates HIF1 activation during seahorse assays. As 
expected, DFO induced a glycolytic switch characterized by reduced mitochondria  O2 consumption (OCR) 
and increased extracellular acidification (ECAR) detected with the XF Mito Stress and the Glycolysis stress test 










































































































































































































Figure 1.  Activation of HIF1α in adipose-tissue cDC ameliorate obesity-induced adipose tissue inflammation. 
(a) Western blot image of HIF1α expression on purified VAT-cDCs. Uncropped image is shown in Suppl. 
Fig. S4. (b) VAT was digested from Hif1α−/− and WT mice fed a WD for 12 weeks. Total numbers of  CD45+ 
hematopoietic cells, cDCs,  CD4+ and  CD8+ T cells were quantified by flow cytometry (n = 6). (c) Graph indicate 
 FoxP3+ Tregs/CD4+ and  CD4+/CD8+ T cells ratios. (d) IL17 and IFNγ production by spleen, LN and VAT-
infiltrated  CD4+ T cell was evaluated by flow cytometry. Bars represent mean ± SEM (n = 5). (e) Quantitative 
RT-PCR analysis for gene expression in VAT from obese Hif1α−/−. Expression levels of all genes were normalized 
against GAPDH RNA and compared to WT mice, which was set as 1. Error bars indicate the geometric mean 
of 8 biological replicates. (f) Fasting glucose, (g) insulin and (h) adiponectin were detected by ELISA. Bars 
represent mean ± SEM (n = 6). Statistical analysis was performed with Student’s test or one-way ANOVA, 
*p < 0.05, **p < 0.01 and ***p < 0.0005.
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subsets, cDC1 and cDC2 (Suppl Fig. S3c,d). DFO treatment alone did not affect expression of co-stimulatory 
molecules (Fig. 3c).
Despite a shift towards aerobic glycolysis, a functional electron transport chain and glutamine-derived car-
bon may still be required for cellular function. Indeed, in tumour cells, metabolic adaptation under hypoxia 
involves a switch from glucose to glutamine as a source of carbon for the synthesis of fatty  acids25. We therefore 
tested glutamine consumption, which was indeed increased in DFO-treated compared to control cells (Fig. 3d).
During the reverse TCA cycle, glutamine-derived citrate can be transported to the cytoplasm to generate 
acetyl-CoA, necessary for anabolic reactions such as fatty acid synthesis. In tumour cells, HIF1α-induced uptake 
and reduction of glutamine induces lipid synthesis and storage in lipid droplets (LD). Interestingly, intracellular 
accumulation of lipids has been associated with poor cDCs activation and function in  tumours26. Consistent with 
an increased glutamine uptake, DFO-treated cells exhibit increased intracellular lipid accumulation in vitro and 
in vivo as detected by bodipy staining (Fig. 3e,f). Similar results were observed with DMOG and hypoxia treat-
ment (Suppl. Fig. S3e). DFO-induced intracellular lipid accumulation was HIF1α dependent (Fig. 3g). Uptake of 
C16-Bodipy (palmitate) was unchanged after DFO stimulation in vitro and in vivo suggesting that lipid droplets 
accumulation is not mediated by lipid uptake but rather lipid synthesis (Fig. 3h,i). Transcriptional levels of 
the hypoxia-inducible lipid droplet-associated protein (Hilpda), which is involved in intracellular neutral lipid 
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Figure 2.  Hif1α deletion in cDCs promotes atherosclerotic plaque formation. Hif1α−/− → Ldlr−/− and 
WT → Ldlr−/− mice were fed a WD for 12 weeks. (a) Flow cytometry analysis of aortic-infiltrated cDCs for 
Hypoxiprobe staining. (b) Aorta was enzymatically digested and the presence of  CD45+ hematopoietic cells, 
cDCs,  CD4+ T cells,  CD8+ T cells and  FoxP3+ Tregs were quantified by flow cytometry. Representative dot 
plot from aorta infiltrated  CD45+ cells. Bars represent mean ± SEM (n = 5). (c) IFNγ and IL17 production was 
analysed by flow cytometry in spleen’s and dLN’s  CD4+ T cell. Dot plot is representative of 3 independent 
experiments. Bars represent mean ± SEM (n = 6). (d) Representative Sirius red staining of aortic root. (e) 
Representative images of en face oil red O staining of atherosclerotic lesions in aorta and (f) quantification of 
atherosclerotic lesion size. Bars indicate mean ± SEM (n = 10). (g) Total cholesterol in obese mice (n = 10). (h) 
Quantitative RT-PCR analysis for gene expression in perivascular fat from obese Hif1α−/−. Expression levels of all 
genes were normalized against GAPDH RNA and compared to WT mice, which was set as 1. Error bars indicate 
the geometric mean of 7 biological replicates. (i) For in vivo antigen presentation, CFSE-labelled OTII cells 
were transferred i.v. one day before immunization with 200 μg OVA i.p. Three days later, frequency and division 
of proliferating OT-II T cells were analysed in aorta, LN, VAT and Spleen from Hif1α−/− and WT mice by flow 
cytometry. Dot plots show gating strategy for  CFSE+ OTII cells. Histograms show dilution of  CFSE+ OTII gated 
cells and are representative of 3 independent experiments. Statistical analysis was performed with Student’s test, 
*p < 0.05, **p < 0.01 and ***p < 0.0005.
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To test if glutamine metabolism was responsible for lipid accumulation in cDCs, cells were treated with the 
fatty-acid synthase inhibitor TOFA and the glutamine antagonist DON. Inhibition of fatty-acid synthesis and glu-
tamine usage, significantly reduced lipid droplets accumulation in DFO-treated cells (Fig. 3k). Collectively, these 
data suggest that HIF1α activation in cDCs stimulates fatty-acid synthesis and accumulation in lipid droplets.
HIF1α‑mediated lipid droplets accumulation suppresses cDC activation. Accumulation of lipids 
in DCs has been shown to impair their antigen-presenting function in tumours. Mice with deleted expression of 
HIF1α on cDCs exhibit increased aortic and VAT inflammation. Thus, we tested whether DFO treatment could 
alter cDCs function in vitro. Indeed, DFO treatment significantly reduces cDCs stimulatory capacity in a mixed-
leukocyte reaction (MLR). This effect was reverted after fatty-acid synthesis inhibition with TOFA (Fig.  4a). 
Similarly, pre-treating cells with DFO reduces cDC cytokine production after LPS treatment (Fig. 4b,c). Thus, 
similar to tumour-infiltrating DCs, lipid-laden cDC exhibit reduced immunogenicity.
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Figure 3.  Hif1α activation induces intracellular lipid accumulation. (a–k) Bone-marrow cells were harvested 
from WT and Hif1α−/− mice and cultured 7–8 days with recombinant Flt3L to obtain cDCs. Cells were then 
incubated 1 or 2 days with DFO to activate Hif1α. Uncropped image is shown in Suppl. Fig. S4. (a) Expression of 
Hif1α in cDCs detected by Western blot. (b) cDC were purified, counted and plated in a XF96 culture plate. O2 
consumption rate (OCR) and medium acidification (ECAR) were measured in real time under basal conditions 
and in response to indicated inhibitors. Graph are representative of 4 independent experiments. (c) Graph 
indicate expression of CD86 and CD40 in untreated and DFO-treated cells (n-3). (d) Glutamine in medium was 
detected by ELISA (n = 5). (e) Intracellular neutral lipids were detected using Bodipy staining by flow cytometry 
(n = 3). Histogram is representative of 5 independent experiments. (f) Bodipy staining from in vivo DFO-treated 
cDCs. (g) Similar to F, but Bodipy stain was performed in control and DFO-treated Hif1α−/− and WT cells. 
Histograms are representative of x independent experiments. (h) cDCs were incubated with Bodipy FL C16 
to evaluate lipid uptake by flow cytometry (n = 3). (i) Bodipy FL C16 staining from in vivo DFO-treated cDCs. 
(j) Quantitative RT-PCR analysis for Hilpda expression from WT and Hif1α−/− in cDCs upon DFO treatment. 
Expression level was normalized against GAPDH RNA and compared to untreated conditions, which was set 
as 1. Error bars indicate the geometric mean of triplicates. (k) As in e, but cells were pre-incubated with DFO 
and then treated with TOFA and DON overnight. Lipid accumulation was detected with Bodipy staining. 
Histograms are representative of 3 independent experiments. Statistical analysis was performed with Student’s 
test, *p < 0.05, **p < 0.01 and ***p < 0.0005.
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Lipid accumulation in cDCs alters the expression of lipid mediators. Neutral lipid stored in LD 
are mobilized by lipases to provide metabolic energy (through fatty acid oxidation) and lipids for membrane 
synthesis. However, recently, it has become evident that LD function as a major intracellular pool of arachidonic 
acid, which is the precursor for eicosanoid  biosynthesis27. In addition, LD can often interact with peroxisomes 
apparently facilitating peroxisomal fatty acid  oxidation28. To investigate a possible consequence of lipid accu-
mulation and the synthesis of lipid mediators, we performed a lipid mediator profiling of DFO-treated and 
control cells (Fig. 5a,b). In these incubations, we identified mediators from all four major fatty acid metabolomes 
(Table S1). Production of prostaglandins and leukotrienes remained unchanged after DFO treatment, probably 
due to the absence of TLR stimulation (Table S1). However, incubation of these cells with DFO significantly 
increased resolvin D2 (RvD2) and thromboxane  B2  (TXB2) a stable metabolite of  TXA2 (Fig. 5c,d) concentra-
tions. Accordingly, key enzymes contributing to the generation of resolvins were elevated in WT compared to 
 HIF1−/− VAT-cDCs from obese mice (Fig. 5e). RvD2 is a pro-resolving lipid-mediator that was recently shown 
to suppress T cell responses and to decrease TLR4 expression in  monocytes29. Similarly,  TXA2 modulates DC-T 
cell interaction and adaptive immune  responses30. Interestingly, treatment with RvD2 or deletion of the  TXA2 
receptor, TP, significantly delays atherosclerosis  progression31. Consistent with previous observations, treatment 
of cDCs-T cell cultures with RvD2 and TP agonist (I-Bop) reduces T cell proliferation in vitro (Fig. 5f). Simi-
larly, the inhibitory effect of HIF1α activation in cDCs, was partially reverted with the TP antagonist SQ29548 
(Fig. 5g). Thus, this data suggest that intracellular accumulation of lipids also impacts the production of bioac-
tive lipid mediators by cDC.
Discussion
The transcriptional factor HIF1α plays a central role in cellular adaptation to hypoxia. Physiologic  O2 tension 
found in tissues varies between 2 and 9%. Hypoxic niches can be observed in a range of tissues including bone 
marrow, medulla of the kidney, intestinal epithelial and  thymus32–34. Tissue oxygenation can be severely disrupted 
during pathological conditions such as obesity, solid tumours, stroke and inflammation leading to hypoxia and 
HIF1 pathway  activation35–37. In obesity, HIF1 stabilization is propagated by mitochondrial ROS  production14. In 
either of these conditions, HIF1α initiates a transcriptome response to help the cells adapt to a hostile environ-
ment. For example, HIF1α induces production of angiogenic factors to promote blood vessel formation; switches 
cellular metabolism to anaerobic glycolysis; reduces reactive oxygen species (ROS) and upregulates BCL-XL 
expression thus promoting cell  survival38,39.
The link between HIF1 and inflammation has been increasingly appreciated over recent years. Inflammatory 
conditions are frequently characterized by tissue hypoxia, ROS production and HIF1α stabilization due to altered 
metabolic supply/demand  ratios40. HIF1α activation in adipose tissue hypoxia is a triggering factor for obesity-
induced  inflammation41. Similarly, arterial wall thickening and inflammatory deposition in the atherosclerotic 
plaque leads to HIF1α stabilization, which appears to promote disease  progression18. This pro-inflammatory 
effect appears to be partially mediated by HIF1α activation in myeloid cells. Indeed, mice with myeloid-specific 
deletion of HIF1α (via lysozyme M-Cre) exhibit improved glucose metabolism, reduced adipose tissue inflam-
mation and decreased atherosclerotic plaque  formation42,43. With this in mind, we investigated the implications 
of HIF1α activation in cDCs and its physio-pathological consequences in obesity-induced chronic inflammation.
In this study, we found that inhibition of HIF1α in cDCs promotes adipose tissue inflammation and acceler-
ates the development of atherosclerosis. Deletion of HIF1α appears to unleash cDC activation with an increased 
in IL12 production and induction of  IL17+ T cells. Not apparent difference on lymph node migration and 
phagocytosis could be detected but this is not an exhaustive study and other mechanisms may be involved. These 
findings oppose the anti-inflammatory effect observed in myeloid cells. Of note, HIF1 transcription has also 
been shown to activate multiple anti-inflammatory pathways such as the expression of arginase 1 and VEGF in 
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Figure 4.  Hif1α activation impairs cDC function. (a) Antigen presentation capacity and activation of 
DFO-treated cDCs was evaluated by MLR. When indicated, cells were also treated with the fatty-acid 
synthesis inhibitor TOFA. T cell proliferation was assessed by CFSE dilution by flow cytometry. Histograms 
are representative of 3 independent experiments. Bar graph indicates proliferation index analysed by flow 
cytometry. (b) Cells were treated overnight with DFO and then stimulated with LPS for 6 h or overnight. 
Intracellular IL-12 production was evaluated by flow cytometry 6 h after stimulation. Dot plots are 
representative of 3 independent experiments. (c) Cytokines were measured in the supernatant WT cDCs after 
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Treg  differentiation44. Therefore, it appears that HIF1 regulates cell effector function in a cell-dependent manner. 
Contrary to pro-inflammatory macrophages, cDCs in steady-state are poised to suppress immune responses in 
tissue, which may account for the phenotype observed. Indeed, cDC are important for the control of adipose 
tissue homeostasis while Flt3L-mediated expansion of cDCs protects mice from  atherosclerosis15,45. Along those 
lines, expression of HIF1α in intestinal dendritic cells, which are crucial for the maintenance of mucosal immune 
homeostasis, suppresses colitis-induced  inflammation12. These results suggest that activation of HIF1α facilitates 
cDCs cellular adaptation and survival, allowing them to pursue their anti-inflammatory function.
A key feature of the HIF1 transcriptional response is the upregulation of genes encoding glycolytic enzymes, 
glucose transporters and the pyruvate dehydrogenase kinase Pdk1 thereby shunting pyruvate away from 
 mitochondria6. Under these conditions, mitochondria are not supplied with glucose-derived acetyl-CoA, a 
central biosynthetic precursor for lipid synthesis. To compensate for this effect, recent studies in tumor cells 
have shown a complementary switch towards glutamine metabolism to support anabolism and growth under 
hypoxic  conditions46. In cDCs, glutamine-derived lipid synthesis results in the accumulation of lipids in LDs. 
Interestingly, cDCs in solid tumors, which are in general hypoxic, are also characterized by LD accumulation and 
an anti-inflammatory  phenotype26. Indeed, similar findings were described as a result of the ER stress response 
factor XBP1 activation in ovarian tumor-infiltrated  cDCs47. XBP1 regulates HIF1α pathway activation and is 
essential for cell survival under hypoxic  conditions48.
The mechanism by which lipid-laden DCs acquire a tolerogenic function is unclear. Recently it has been sug-
gested that LD in tumor-DCs contain oxidatively truncated electrophilic lipids that interfere with cross-presenta-
tion49. However, the role of lipid mediators is not known. Lipid mediators are considered key signalling molecules 
in inflammation as they are locally produced through specific biosynthetic pathways in response to extracellular 
 stimuli50. Once produced, they bind to their cognate G protein receptor to exert their function after which they 
are rapidly inactivated through specific  processes50. Lipid mediators are involved in many physiological processes 



























































































































Figure 5.  HIF1 stabilization induces changes in the cDC lipid mediator profile. DFO-treated cDCs cells 
were harvested for lipidomic analysis. Lipid mediators were extracted using solid-phase extraction techniques 
and identified using liquid chromatography-tandem mass spectrometry-based lipid mediator profiling. (a) 
2-dimensional score plot of plasma LM-SPM and (b) corresponding 2-dimensional loading plot. Gray ellipse 
in the score plot denotes 95% confidence regions. (c) Bars representing significant increase of RvD2, and (d) 
 TXB2 after DFO treatment (n = 3). (e) Quantitative RT-PCR analysis for early Pla2 and late, Alox15 and Alox5, 
enzymes involved in the synthesis of resolvins in VAT-cDCs from WT and Hif1α−/− obese mice. Expression level 
was normalized against GAPDH RNA and compared to Hif1α−/− cDCs, which was set as 1. Error bars indicate 
the geometric mean of triplicates. WT cDCs were pre-treated with DFO and then the TXA2 agonist I-Bop or 
RvD2 when indicated. cDC stimulatory capacity was evaluated by MLR. T cell proliferation was assessed by 
CFSE dilution by flow cytometry. Histograms are representative of 2 independent experiments. (f) As in E but 
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can be subcategorized into different groups, such as AA-derived eicosanoids (e.g. prostaglandins); and the newly 
identified anti-inflammatory and pro-resolving mediators derived from ω-3 polyunsaturated fatty acids such as 
 resolvins52. They can have pro- or anti-inflammatory function: for example, pro-inflammatory lipid mediators, in 
general terms, include prostaglandins and leukotrienes, while pro-resolving mediators include lipoxins, resolvins, 
maresins and  protectins52. The effect of several lipid mediators on DC function is well  documented34,53, however, 
production of these mediators by cDC and its regulation remains uncharacterized. We here show that activa-
tion of HIF1 pathways promotes the expression of RvD2 and  TXB2, two mediators involved in the regulation 
of T cell responses. The profile of lipid mediators is not only regulated at the enzymatic levels but also through 
substrate availability that may differ between tissues and physiological and pathological  conditions54. Our data 
indicated that HIF1α activation can alter the production of lipid mediators through LD accumulation. How the 
lipid mediator profile is altered in tissue-cDCs in vivo will require further investigations.
There is currently an increasing interest in targeting immunometabolic pathways in inflammatory diseases 
and cancer. However, questions arise about the specificity and off-target effect of many metabolic drugs. Although 
deletion of HIF1α in cDCs results in increased obesity-tissue inflammation, therapeutic treatment with the selec-
tive HIF1α inhibitor PX-478 slows down the progression of obesity-induced adipose tissue  inflammation55. This 
opposite effect can be mediated through inhibition of HIF1α activation in recruited inflammatory macrophages, 
inhibition of HIF1-dependent VEGF production or directly on  adipocytes56–59. Thus, the use of HIF1α inhibitors 
should be evaluated with caution as it may increase the risk of obesity-induced inflammatory complications such 
as psoriasis and rheumatoid arthritis or risk of infections.
Methods
Mice. B6.129s7-Ldlrtm1Her/J (Ldlr-KO), B6.129-Hif1atm3Rsjo/J  (HIFaloxp) and B6.Cg-Tg(TcraTcrb)425Cbn/J 
(OT-II) mice were purchased from Jackson Laboratory (US); C57BL/6 were purchased from Charles River labo-
ratories (UK); Zbtb46-Cre+ mice were kindly provided by Nussenzweig (The Rockefeller University, NY). As 
previously  described15, mice were housed in temperature- and humidity-controlled rooms at 22 °C and 55% 
humidity, with a 12 h light/12 h dark cycle. Mice were fed Chow or Test Diet AIN-76A (Test Diet IPS Ltd) and 
given water ad libitum; animals were rehoused in clean cages weekly. 15 g of Z-NEST (IPS Ltd) was used as nest-
ing material to help regulate temperature and light levels. For chimeras, Ldlr-KO male mice were γ-irradiated 
twice with 500 rad 3 h apart. Three hours later, mice were reconstituted with marrow cells (3 × 106) that had been 
harvested from the femurs and tibias of Hif1α−/− and control WT littermates. Mice were maintained on acidified 
water during the critical 4 weeks reconstitution period. Mice fed Western diet that failed to gain more than 20% 
of body weight were excluded from the study. All animal experimental protocols were carried out in accordance 
with UK government Home Office licensing procedures and regulations, and approved by QMUL’s Animal Wel-
fare and Ethical Review Board (AWERB-7007443).
Flow cytometry staining. VAT was collected from euthanised mice, from the mesenteric, retroperitoneal 
and abdominipelvic fat depot sites. The tissue was weighed and digested with 2370 U/ml Collagenase II (Sigma) 
and 23 U/ml DNase (Sigma)/gram of VAT. Immune cells present in the vascular fraction were obtained after 
centrifugation and lysed of red blood cells before staining. For aortic-single cell preparation, perivascular fat 
and cardiac muscle was carefully removed and aorta isolated under a dissecting microscope. Aortic segments, 
including aortic sinus, aortic arch and thoracic aorta were digested with 607.5 U/ml collagenase I, 187.5 U/ml 
collagenase XI, 90 U/ml hyaluronidase and 90 U/ml DNase in Hank’s balanced salt solution for 1 h at 37 °C. 
Single cell suspensions were stained with fixable Aqua dead cell stain (Invitrogen) to exclude dead cells from 
analysis and surface markers; DX5-FITC, CD16/32-FITC, F4/80-PerCP, CD206-BV421, CD11c-BV605, CD11c-
PE-CY7, CD103-APC, MHCII-AF700, CD11b-AF780, MertK-PE, CD45-PE-CF594, CD64-PE-Cy7, CD8-
FITC, Ly6G-BV421, NK1.1-BV605, CD3-AF700, CD3-BV421, CD86-PE, CD4-PE-Cy7, CD4-PeCP-Cy5.5, 
B220-PerCP, B220-FITC (eBioscience/BioLegend/BD Bioscience/R&D/ThermoFisher). Samples were stained 
at 4 °C for 30 min and fixed at 4 °C for 30 min with 1% PFA. For intracellular staining of FOXP3-PE (Bioleg-
end), samples were incubated in permeabilization/fixation buffer (eBioscience) at 4 °C for 30 min and washed 
in permeabilization buffer before staining with fluorescently conjugated primary antibody at 4 °C for 30 min 
in permeabilization buffer. For hypoxia studies, mice were injected i.p. with 60 mg/kg bw of Hypoxiprobe™-1 
(Pimonidazole Hydrochloride, Hypoxiprobe). Two hours later, aortas were harvested, digested and stained with 
anti-pimonidazole monoclonal antibody-PE (Hypoxiprobe). For intracellular cytokine analysis, immune cells 
were isolated from tissues and stimulated with 20 ng/ml Phorbol 12-myristate 13-acetate (PMA) (Sigma) and 
1 µg/ml Ionomycin (Sigma) for 6 h, in the presence of 10 µg/ml Brefeldin A (Sigma) for the last 5 h. For intracel-
lular staining, samples were first fixed with BD Cytofix/Cytoperm kit (BD Bioscience) and stained for 15 min 
with IFNγ-APC and IL-17-PE antibodies (Biolegend) following manufacturer’s instructions. Samples were then 
analysed by flow cytometry using a LSR Fortessa (BD Biosciences) and FlowJo version 10 software.
DC innate and adaptive responses. cDC allostimulatory capacity was evaluated in vitro. For this, bone-
marrow (BM) cells were harvested from Hif1α−/− and WT mice injected previously with B16-Flt3l and cul-
tured in the presence of 0.2 µl/ml recombinant Flt3 ligand (Invitrogen) for 8 days. Cells were then treated with 
250 µM DFO (Desferrioxamine, Sigma) overnight. Alternatively, BM-cDCs were treated with DFO for 2 days 
and 1.2 µM TOFA (5-(Tetradecyloxy)-2-furoic Acid, Sigma) for the last 24 h.  CD4+ T cells were harvested from 
the spleen of BALBc mice by  CD4+ bead positive selection (MACS Miltenyi Biotec) and labelled with CFSE 
3 μM (Invitrogen). Cells were mixed at a ratio of 1:5 (5 × 104  CD11c+ cDCs: 2.5 × 105  CD4+ T cells/well) and 
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heptan-2-yl]-5-heptenoic acid) or 1 μM of SQ-29548 ([1S-[1α,2α(Z),3α,4α]]-7-[3-[[2-[(phenylamino)carbonyl]
hydrazino]methyl]-7-oxabicyclo[2,2,1]hept-2-yl]-5-heptenoic acid,) were added to the cultures. T cell division 
was assessed by CFSE dilution by flow cytometry and cytokine production in the supernatant by ELISA.
For in vivo cDC T cell stimulatory capacity, mice were injected intravenously with ovalbumin-specific OTII 
cells purified from spleen and lymph nodes by  CD4+ bead positive selection (MACS Miltenyi Biotec) and labelled 
with CFSE 3 μM (Invitrogen). The next day, mice were immunized with 200 μg of Ovalbumin (Sigma) i.p. Three 
days later, immune cells were isolated from spleen, lymph nodes, aorta and visceral adipose tissue and OT-II cell 
division was evaluated by CFSE dilution by flow cytometry. Alternatively, mice were immunized with 200 μg of 
Ovalbumin (Sigma) i.p. and cDCs from VAT and dLN were isolated four hours later, purified by cell sorting and 
cultured with CFSE-labelled OT-II cells at a ratio of 1:5 in vitro. CFSE dilution was evaluated by flow cytometry. 
To evaluate ovalbumin uptake, mice were injected i.p. with 10 μg of OVA-Alexa Fluor-555. Two hours later, 
visceral adipose tissue was harvested and digested. Ova uptake by cDCs was analysed by flow cytometry.
BM-cDCs were treated with DFO overnight. Cells were then plated at  106 cells/well and stimulated with 
20 ng/ml LPS (sigma) in the presence of DFO. After culturing overnight, the supernatant was collected and 
levels of IL-10, IL-6 and IL-12p70 were determined by murine ELISA (eBioscience). Alternatively, cells were 
stimulated with LPS for 6 h and in combination with 10 µg/ml Brefeldin A (Sigma) for the last 5 h. Intracellular 
expression of IL-12 was assessed by flow cytometry as previously described. For in vivo IL-12 production, mice 
were immunized with 1 μg of LPS (Sigma), 2 h later, tissues were harvested, digested and incubated with 10 µg/
ml Brefeldin A (Sigma) for an additional 4 h.
Western blotting. Western blotting was performed as describe  in15. Protein lysates were prepared from 
purified cDCs using RIPA buffer with phosphatase and protein inhibitors (Pierce). Proteins were separated with 
SDS-PAGE and transferred to Immobilon™ PVDF membrane (Millipore). Membranes were blocked for 1 h at 
room temperature in PBST containing 5% (w/v) milk, incubated overnight at 4 °C with anti-Hif1α antibody 
(Cell signalling) and subsequently with HRP-conjugated secondary antibody (Amersham Bioscience). Blotted 
proteins were detected using an EZ-ECL™ HRP chemiluminescence detection kit (Biological Industries) and 
exposed on to Hyperfilm™ photo film (Amersham).
Quantitative Real‑time PCR. RT-PCR was performed as previously  described15. Briefly, RNA from 
100 mg VAT was isolated using RNeasy Lipid Tissue Mini Kits (Qaigen) following the manufacturer’s instruc-
tions. Reverse transcription to cDNA was performed using High-Capacity RNA-to-cDNA Kits (Applied Biosys-
tems) and stored at − 80 °C. Gene expression was performed using SYBR Green Supermix (Bio-Rad), accord-
ing to the manufacturer’s instructions, and analysed using a CFX connect light cycler (Bio-Rad). Gene-relative 
expression was calculated using the ΔΔCT method and normalised to a reference control (GAPDH) with control 
sample set as 1. Average ratio from replicates was calculated using geometric mean. The following primers were 
used for the analysis (Invitrogen, UK);
IL10_forward: AAA CAA AGG ACC AGC TGG AC
IL10_reverse: TTC CGA TAA GGC TTG GCA AC
TNFα_forward: TCG TAG CAA ACC ACC AAG TG
TNFα_reverse: TTT GAG ATC CAT GCC GTT GG
IL6_forward: TAG TCC TTC CTA CCC CAA TTT CC
IL6_reverse: TTG GTC CTT AGC CAC TCC TTC 
IL1_forward: AAC CTG CTG GTG TGT GAC GTT C
IL1_reverse: CAG CAC GAG GCT TTT TTG TTG T
INFγ_forward: CAG CAA CAG CAA GGC GAA A
INFγ_reverse: CTG GAC CTG TGG GTT GTT GAC 
IL17_forward: AAA GCT CAG CGT GTC CAA AC
IL17_reverse: TTC TGG AGC TCA CTT TTG CG
CCL2_forward: GCT GGA GCA TCC ACG TGT T
CCL2_reverse: ATC TTG CTG GTG AAT GAG TAG CA
CCL17_forward: GGA TGC CAT CGT GTT TCT GA
CCL17_reverse: GCC TTC TTC ACA TGT TTG TCT TTG 
Alox15_forward: GAC ACT TGG TGG CTG AGG TCTT 
Alox15_reverse: TCT CTG AGA TCA GGT CGC TCCT 
Alox5_forward: TCT TCC TGG CAC GAC TTT GCT G
Alox5_reverse: GCA GCC ATT CAG GAA CTG GTAG 
Pla2g4a_forward: GAT GAG GCT CAA GGA CCC AAA G
Pla2g4a_reverse: GAA TAA AGC CGA GTC GCT CAC C
Apidoq_forward: GAC GTT ACT ACA ACT GAA GAG C
Apidoq_reverse: CAT TCT TTT CCT GAT ACT GGT C
GAPDH_forward: GGC TCA TGA CCA CAG TCC A
GAPDH_reverse: CAC ATT GGG GGT AGG AAC AC
Whole mount aorta and aortic root staining. Immediately after euthanisation, the WD fed mice were 
flushed free of blood with cold PBS. Using a dissection microscope, the heart and aorta, including the arch with 
its branching vessels, thorax and abdominal section, were carefully excised and attached fat removed. The aorta 
was cut away from the heart just above the aortic synapse and both fixed in 4% PFA overnight. The aorta was 
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opened longitudinally for en face Oil Red O staining. To prepare the stain 3 parts 5 mg/ml Oil Red O solution in 
isopropanol was diluted with 2 parts distilled water and allowed to solubilise for 1 h prior to 0.45 μm filtration. 
The aortas were washed in distilled water then transferred into freshly prepared Oil Red O solution for 15 min 
at room temperature (RT). They were then washed in 60% isopropanol for 5 min. This was repeated until no 
more red colour came out into the wash. Then the aortas were transferred into distilled water. Glycerol gelatin 
(Sigma) was used to mount the aortas onto slides and they were visualised using a M205 FA microscope (Leica). 
Images of the aortas were analysed blindly using ImageJ to quantify the percentage lesion density. The top half 
of the hearts were paraffin embedded, sectioned and mounted onto slides ready for Sirius Red staining by the 
BCI Pathology Core Service. The sectioned were visualised using a Pannoramic 250 High Throughput Scanning 
Microscope.
Lipid mediator profiling. Lipid profiling was performed by QMUL lipidomic facility as described  in60. 
Cell incubations were placed in 2 volumes of ice-cold methanol (Thermo Fisher Scientific) containing internal 
standards  (d8-5S-hydroxy eicosatetraenoic acid,  d5-RvD2,  d5-LXA4,  d4-PGE2, and  d4-leukotriene  LTB4 (all from 
Cayman Chemical); 500 pg each were added to the sample. LMs were extracted and identified as described 
 previously60. Briefly, the samples in methanol were incubated for 45 min at − 20 °C for protein precipitation, 
and centrifuged at 1900g at 4 °C for 10 min. The methanol content of the supernatant was evaporated to less 
than 1 ml using nitrogen gas stream, and the LMs were extracted with automated Extra-Hera system (Biotage, 
Uppsala, Sweden) employing solid-phase extraction. The methyl formate eluates were concentrated and injected 
to liquid chromatography-tandem mass spectrometry (LC–MS/MS) system (LC-20AD HPLC (Shimadzu) and 
SIL-20AC autoinjector (Shimadzu) paired with QTrap 6500 + (ABSciex, Framingham, MA, USA). LMs were 
identified and quantified using multiple reaction monitoring the parent (Q1) and daughter (Q3) ions in negative 
ionization mode. Identification was conducted in accordance with published criteria, matching the retention 
time with authentic and synthetic standards (from Cayman Chemical, prepared in house, or provided by Charles 
N. Serhan, Harvard Medical School, Boston, MA, USA) and identifying at least 6 diagnostic ions from the MS/
MS spectra PMID: 29363065.
Metabolic assays. Adiponectin, Insulin (Merk Millipore), and total cholesterol (Abcam) were measured 
in the plasma from fasted mice by ELISA. Glucose metabolism was assessed by Glucose (GTT) and Insulin 
(ITT) tolerance tests after 6 h fasting as previously described  in15. For GTT, mice were administered with 1.5 mg 
d-glucose/g of body weight (Sigma) or 0.5 U insulin/kg of body weight (Actrapid) via intraperitoneal injection 
for ITT. In both cases, blood glucose measurements were taken from tail bleeds at 15, 30, 60, 90, 120, 180 min 
after injection using blood glucose meter and test strips (FreeStyle Optium Neo, Abbott). Body weight and food 
intake was recorded weekly. Weight of total visceral adipose tissue harvested was recorded for cell number cal-
culations and to determine the percentage of body weight.
To test mitochondrial respiration and glycolysis, BM-cDCs were treated with DFO overnight and plated at 
2 × 105/well onto Seahorse XF96 cell plates. Mito stress and Glycolysis stress test were performed with the Sea-
horse XF96 Extracellular Flux Analyzer (Agilent) flowing manufacturer’s instructions. Glutamine concentration 
was evaluated in supernatant from overnight DFO-treated BM-cDCs by ELISA (Abcam). For intracellular lipid 
detection, BM-cDCs were incubated with Bodipy FL or Bodipy-C16 (Invitrogen) at RT for 15 min in PBS. For 
ex vivo staining, mice were injected 50 μg/g bw DFO i.p. for two consecutive days Mice were euthanised the 
following day and spleens were digested with 400 U/ml Collagenase D (Roche). Splenocytes were stained with 
Bodipy FL or Bodipy-C16 as explained above.
Statistical analysis. Statistical analysis was carried out with Graph Prism 8 (GraphPad Software LLC) and 
significance was evaluated by Student’ two tailed t test. For GTT and ITT, statistical significance was evaluated 
with 2-way ANOVA followed by post-hoc Bonferroni test. Differences within means were significant when P 
values of 0.05 or less. Normality was assessed using the Kolmogorov–Smirnov and Shapiro–Wilk test. Data are 
represented as mean and standard deviation.
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